Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to control returning lung cancer in targeted patients

NCT ID NCT07279935

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This study is for people with a specific type of lung cancer (EGFR-mutant) that has spread to other parts of the body after they finished a previous treatment (osimertinib). The goal is to see if combining osimertinib with chemotherapy can help control the cancer for longer. About 100 participants in China will receive this combination and be monitored for how long the cancer stays stable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for pre-screening: 1. Prior complete surgical resection (R0) and adjuvant osimertinib in EGFRm resectable SIB-IIIA NSCLC (AJCC 7th edition). 2. Off-treatment recurrence (including completed 3 years adjuvant osimertinib \& discontinued adjuvant osimertinib before 3 years due to non-recurrence reason). 3. Newly diagnosed distant recurrent NSCLC (IVA or IVB) (per Version 9 of the International Association for the Study of Lung Cancer \[IASLC\] Staging Manual in Thoracic Oncology). 4. ≥6 months interval between recurrence and completion or discontinuation of adjuvant osimertinib. 5. Histologically/cytologically confirmed nonsquamous NSCLC (Investigators confirmed recurrence of primary lesion allowed if biopsy not available) 6. No prior systemic anti-cancer therapy after adjuvant therapy, but can receive local therapy (including surgery, radiotherapy, etc. per investigator choice). 7. Patients with asymptomatic or stable CNS metastases allowed. Inclusion Criteria for screening: 1. Male or female, at least 18 years of age. Type of patient and disease characteristics 2. EGFR mutation (Exon 19del/Exon 21 L858R)-reconfirmed for study entry (mandatory undergo NGS by plasma, and tissue if applicable). 3. Life expectancy \>12 weeks at Day 1. Exclusion Criteria: 1. Patients with only local/regional recurrence. 2. Spinal cord compression and symptomatic brain metastases. 3. Past medical history of ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. 4. Adjuvant osimertinib therapy was discontinued due to the occurrence of severe adverse events. 5. Prior with other adjuvant EGFR-TKIs (excluding osimertinib). 6. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib. 7. History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib. 8. Contraindication for pemetrexed and cisplatin/carboplatin according to local approved label.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bronchial neoplasm bronchogenic carcinoma lung disorder lung neoplasm neoplasm Neoplasms by Site non-small cell lung carcinoma respiratory system disorder respiratory tract neoplasm Thoracic Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    24 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    NOT_YET_RECRUITING

    Beijing, 100021, China

  • Research Site

    RECRUITING

    Beijing, 100044, China

  • Research Site

    RECRUITING

    Beijing, 100142, China

  • Research Site

    NOT_YET_RECRUITING

    Chengdu, 610031, China

  • Research Site

    RECRUITING

    Chengdu, 610041, China

  • Research Site

    RECRUITING

    Chongqing, 400016, China

  • Research Site

    RECRUITING

    Fuzhou, 350001, China

  • Research Site

    RECRUITING

    Fuzhou, 350005, China

  • Research Site

    NOT_YET_RECRUITING

    Guangzhou, 510080, China

  • Research Site

    WITHDRAWN

    Guangzhou, 510100, China

  • Research Site

    NOT_YET_RECRUITING

    Guangzhou, 510289, China

  • Research Site

    RECRUITING

    Hangzhou, 310016, China

  • Research Site

    RECRUITING

    Hefei, 230022, China

  • Research Site

    WITHDRAWN

    Hefei, 230031, China

  • Research Site

    WITHDRAWN

    Jinan, 250014, China

  • Research Site

    RECRUITING

    Jinan, 250014, China

  • Research Site

    WITHDRAWN

    Kunming, 650118, China

  • Research Site

    RECRUITING

    Nanchang, 330006, China

  • Research Site

    WITHDRAWN

    Nanjing, 2100008, China

  • Research Site

    RECRUITING

    Nanjing, 210009, China

  • Research Site

    RECRUITING

    Ningbo, 315010, China

  • Research Site

    RECRUITING

    Shanghai, 200030, China

  • Research Site

    WITHDRAWN

    Shanghai, 200120, China

  • Research Site

    WITHDRAWN

    Shanghai, 200433, China

  • Research Site

    RECRUITING

    Shenyang, 110004, China

  • Research Site

    RECRUITING

    Shenyang, 110042, China

  • Research Site

    RECRUITING

    Tianjin, 300060, China

  • Research Site

    RECRUITING

    Wuhan, 430022, China

  • Research Site

    RECRUITING

    Wuhan, 430030, China

  • Research Site

    RECRUITING

    Xi'an, 710004, China

  • Research Site

    WITHDRAWN

    Xi'an, 710061, China

  • Research Site

    RECRUITING

    Zhengzhou, 450008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.